A Novel Multiplex Immunoassay for the Early Detection of Bladder Cancer
To improve upon the non-invasive detection of bladder cancer by further validating a multiplex ELISA assay directed at a bladder cancer-associated diagnostic signature in voided urine samples of patients with a high risk of developing bladder cancer.
⁃ Participants must be:
• Age 50 years or older
• \>20 pack year history of tobacco exposure
• Free of any malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years. Patients with localized prostate cancer who are being followed by an active surveillance program are also eligible.
• Scheduled to be evaluated in the Pulmonary Rehab Clinic or Lung Cancer Screening Clinic
• Willing and able to give written informed consent
• Willing to provide voided urine sample
• Be able and willing to complete semi-annual research clinic visits for 4 years